110 related articles for article (PubMed ID: 22342570)
1. Cetuximab-induced pneumonitis in head and neck cancer patient.
De Vos FY; Driessen CM; Jaspers HC; van Herpen CM; Simons B
Oral Oncol; 2012 Jun; 48(6):e17-8. PubMed ID: 22342570
[No Abstract] [Full Text] [Related]
2. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
3. Rash conclusions from a phase 3 study of cetuximab?
Harrington KJ
Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
[No Abstract] [Full Text] [Related]
4. Acneiform rash secondary to cetuximab plus head and neck radiotherapy.
Mydin AR; Armstrong JG
Radiother Oncol; 2007 Oct; 85(1):171. PubMed ID: 17531339
[No Abstract] [Full Text] [Related]
5. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
6. Cetuximab plus radiotherapy for head and neck cancer.
Armstrong JG
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
[No Abstract] [Full Text] [Related]
7. Cetuximab plus radiotherapy for head and neck cancer.
Cengiz M; Yildiz F; Genc M
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710908
[No Abstract] [Full Text] [Related]
8. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
9. More on cetuximab in head and neck cancer.
Mell LK; Weichselbaum RR
N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
[No Abstract] [Full Text] [Related]
10. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
Budach W; Bölke E; Homey B
N Engl J Med; 2007 Aug; 357(5):514-5. PubMed ID: 17671265
[No Abstract] [Full Text] [Related]
11. Cetuximab plus radiotherapy for head and neck cancer.
Ho AC
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16707760
[No Abstract] [Full Text] [Related]
12. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.
Chan A; Teoh D; Sanghera P; Hartley A
Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312
[No Abstract] [Full Text] [Related]
13. Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?
Brohée D; Henry AR; Castadot P
Acta Clin Belg; 2013; 68(3):237-9. PubMed ID: 24156231
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab plus radiotherapy for head and neck cancer.
Hartig F; Pechlaner C
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710909
[No Abstract] [Full Text] [Related]
15. Cetuximab in squamous cell head and neck carcinomas.
Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant.
Mydin AR; Armstrong JG
Clin Oncol (R Coll Radiol); 2007 Jun; 19(5):365-6. PubMed ID: 17379490
[No Abstract] [Full Text] [Related]
18. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.
Valeriani M; Muni R; Osti MF; De Sanctis V; Minniti G; Ardito F; Maurizi Enrici R
Radiol Med; 2012 Feb; 117(1):125-32. PubMed ID: 21892718
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
20. Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.
Wieczorek A; Hamid A; O'Toole L
Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):496. PubMed ID: 21482459
[No Abstract] [Full Text] [Related]
[Next] [New Search]
